US EditionElanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal - Elanco Animal Health (NYSE:ELAN), Tarsus Pharmaceuticals (NASDAQ:TARS)
Summary by Benzinga
1 Articles
1 Articles
All
Left
Center
1
Right
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal - Elanco Animal Health (NYSE:ELAN), Tarsus Pharmaceuticals (NASDAQ:TARS)
Elanco Animal Health Incorporated (NYSE:ELAN) on Monday announced the sale of certain future tiered royalties and commercial milestones associated with Xdemvy (lotilaner ophthalmic solution) 0.25% for the human health application of lotilaner to Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. The company will use the proceeds to accelerate debt reduction, positioning Elanco to achieve an expected net leverage…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
